Genmab A/S (NASDAQ:GMAB) Rating Increased to Buy at TD Cowen

Genmab A/S (NASDAQ:GMAB) was upgraded by research analysts at TD Cowen from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm currently has a $43.00 price target on the stock. TD Cowen’s target price suggests a potential upside of 51.62% from the stock’s current price.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Truist Financial initiated coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Wolfe Research assumed coverage on shares of Genmab A/S in a research report on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price for the company. Finally, HC Wainwright lifted their price objective on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.81.

Genmab A/S Trading Up 1.6%

Shares of NASDAQ:GMAB opened at $28.36 on Wednesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S has a 52-week low of $21.00 and a 52-week high of $35.43. The company has a 50-day simple moving average of $26.68 and a 200 day simple moving average of $28.35. The company has a market capitalization of $17.68 billion, a P/E ratio of 21.49, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the company. Personal CFO Solutions LLC boosted its stake in shares of Genmab A/S by 3.7% during the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after purchasing an additional 386 shares in the last quarter. Founders Capital Management increased its stake in shares of Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the period. Parallel Advisors LLC increased its stake in shares of Genmab A/S by 11.3% in the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after buying an additional 419 shares during the period. CWM LLC raised its holdings in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after buying an additional 433 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the period. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.